Bharat Parenterals Subsidiary Innoxel Receives USFDA EIR for Vadodara Injectables Facility
Bharat Parenterals Ltd 路 Press Release 路 05 Nov 2026, 8:10 pm
Bharat Parenterals Subsidiary Innoxel Receives USFDA EIR for Vadodara Injectables Facility Bharat Parenterals' subsidiary, Innoxel Lifesciences, received an Establishment Inspection Report (EIR) from the USFDA on 4th Nov'26, successfully closing an unannounced Pre-Approval Inspection conducted between 13th Apr'26 and 20th Apr'26 at its Vadodara finished dosage facility. The USFDA confirmed the plant is ready for commercial operations of a general injectable product with no further questions. This marks the site's second USFDA EIR alongside an existing EU-GMP certification, strengthening its regulated-market CDMO capabilities following its first US commercial launch in Oct'26.
Original exchange filing (PDF)
More announcements from Bharat Parenterals Ltd
- Transcript of Earnings Conference Call of Q2FY27. 路 02 Nov 2026
- Audio Recording of Q2FY27 Earnings Conference Call. 路 30 Oct 2026
- Investor Presentation for the Quarter and Half Year ended on September 30, 2026. 路 29 Oct 2026
- Un-Audited Standalone and Consolidated Financial Results For the Quarter and Half Year Ended On September 30, 2026. 路 29 Oct 2026
- Outcome of the Meeting of the Board of Director of Bharat Parenterals Limited held on October 29, 2026 路 29 Oct 2026
- Approval of Preferential Issue by Shareholders of the Company through EGM Held on October 23, 2026. 路 25 Oct 2026
- Revised Voting Result 路 25 Oct 2026
- Approval of Preferential Issue by shareholders of the company through EGM held on October 23, 2026. 路 24 Oct 2026
